> top > docs > PMC:7074424 > spans > 26880-27257 > annotations

PMC:7074424 / 26880-27257 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
608 159-167 Gene denotes helicase Gene:164045
609 276-284 Gene denotes helicase Gene:164045
612 20-23 Chemical denotes ATP MESH:D000255
613 25-29 Chemical denotes dATP MESH:C026600
614 35-39 Chemical denotes dCTP MESH:C024107
615 78-82 Chemical denotes NTPs
616 88-96 Disease denotes Toxicity MESH:D064420
617 220-228 Disease denotes toxicity MESH:D064420

2_test

Id Subject Object Predicate Lexical cue
32201449-20071563-47217144 84-86 20071563 denotes 88
32201449-16611118-47217145 230-232 16611118 denotes 87
32201449-27064001-47217146 374-376 27064001 denotes 89
T33859 84-86 20071563 denotes 88
T41240 230-232 16611118 denotes 87
T97464 374-376 27064001 denotes 89

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T835 63-73 MOP:0000619 denotes hydrolyzed
T834 145-155 CHEBI:35222;CHEBI:35222 denotes inhibitors
T833 191-201 CHEBI:35222;CHEBI:35222 denotes inhibitors
T832 323-332 CHEBI:23888;CHEBI:23888 denotes druggable

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T270 321-322 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T341 20-23 Chemical denotes ATP http://purl.obolibrary.org/obo/CHEBI_15422|http://purl.obolibrary.org/obo/CHEBI_30616
T343 25-29 Chemical denotes dATP http://purl.obolibrary.org/obo/CHEBI_16284|http://purl.obolibrary.org/obo/CHEBI_61404
T345 35-39 Chemical denotes dCTP http://purl.obolibrary.org/obo/CHEBI_16311|http://purl.obolibrary.org/obo/CHEBI_61481
T347 145-155 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T348 191-201 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T159 0-377 Sentence denotes This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]